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Abstract (226 words) 36 
WHO and its partners aim to interrupt yaws transmission in endemic countries and to certify others as being 37 
yaws-free. Transmission can be assessed using rapid plasma reagin (RPR) tests, reflecting current or recent 38 
infection, but RPR is operationally impractical.  39 
We evaluated changes in antibody levels against two recombinant treponemal antigens, rp17 (also known as 40 
Tp17) and TmpA, after antibiotic treatment given as part of a randomized controlled trial for yaws in Ghana and 41 
Papua New Guinea. Paired serum samples from children aged 6–15 years with confirmed yaws, collected before 42 
and after treatment, were tested for antibodies to rp17 and TmpA using a semi-quantitative bead-based 43 
immunoassay.  44 
Of 344 baseline samples, 342 tested positive for anti-rp17 antibodies and 337 tested positive for anti-TmpA 45 
antibodies. Six months after treatment, the median decrease in anti-rp17 signal was 3.2%, whereas the median 46 
decrease in anti-TmpA was 53.8%. The magnitude of change in the anti-TmpA response increased with 47 
increasing RPR titer fold-change. These data demonstrate that responses to TmpA decrease markedly within 6 48 
months of treatment whereas (as expected) those to rp17 do not. 49 
Incorporating responses to TmpA as a marker of recent infection within an integrated sero-surveillance platform 50 
could provide a way to prioritize areas for yaws mapping. 51 
Key words:  Yaws, antibody, mass drug administration, serosurveillance 52 
Introduction (manuscript: 2436 words) 53 
Yaws, caused by Treponema pallidum subspecies pertenue, is a chronic relapsing and remitting condition of the 54 
skin, bones, and soft tissues. If left untreated, the disease may progress to its tertiary stage, in which irreversible 55 
destruction of soft tissue and bone occur. In 2012, WHO adopted a new approach to yaws eradication based on 56 
community mass treatment with azithromycin followed by active case finding to identify and treat remaining 57 
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cases (1). This is a highly effective intervention for reducing the community prevalence of both active and latent 58 
yaws (2-5). 59 
A major barrier to yaws eradication efforts is the lack of adequate epidemiological data and therefore there is an 60 
urgent need to conduct surveys to identify communities in need of intervention (6). Based on mostly clinic-61 
based data reported to WHO, 15 countries are known to be currently endemic, whilst another 79 countries that 62 
have previously reported cases have in the last ten years either reported only “suspected” yaws cases (3 63 
countries) or provided no information on the current national status of the disease (76 countries) (7). Responses 64 
to a WHO questionnaire suggested that a number of these possibly-formerly-endemic countries may in fact still 65 
be endemic for yaws (7). In 2018, a modelling exercise identified a list of countries to prioritize for active 66 
surveillance: countries where, in the event of ongoing yaws transmission, passive surveillance by the health 67 
system was unlikely to detect it (8).  68 
Large-scale surveillance for yaws is not an easy task. Active yaws prevalence is often low (<1% of the general 69 
population) and symptomatic cases are highly clustered at multiple scales (9, 10), making detection systems 70 
challenging to design and implement. Serology-based approaches may be useful because latent yaws is more 71 
prevalent (range 3–31%) than active yaws in endemic populations (11). Systems that detect latent yaws could 72 
decrease the number of people that need to be tested to conclude with reasonable confidence that infection 73 
was not being transmitted. Initial serological surveys could be used to select areas in which community mass 74 
treatment should be implemented followed by more detailed active case searches.  75 
Serological evidence of yaws requires demonstrable reactivity using two distinct antibody tests: treponemal-76 
specific tests such as the T. pallidum passive particle agglutination [TPPA] test that may remain positive for life, 77 
and non-treponemal tests such as the rapid plasma reagin (RPR) test that measures antibodies against lipoidal 78 
material from the bacterium and/or damaged host cells, and for which reactivity wanes after successful 79 
treatment. The use of the TPPA and RPR in sero-surveys for yaws is impractical because these tests require 80 
venipuncture, collection of whole blood, separation of serum samples and transport of samples using a cold-81 
 on A











chain. They are also somewhat operator dependent. The Dual Path Platform (DPP) Syphilis Screen & Confirm 82 
Assay (Chembio Diagnostics, Medford, NY, USA) is a useful rapid point of care test able to separately detect both 83 
treponemal and non-treponemal antibodies using whole blood, but suboptimal for large surveillance programs 84 
because of its low throughput (12). Use of an approach such as the multiplex bead assay (MBA) would facilitate 85 
large-scale sampling by utilizing dried blood spots collected by finger prick and thereby encouraging integration 86 
with sero-surveys targeting other diseases. 87 
We have previously adapted the recombinant treponemal antigens rp17 (13) and TmpA (14, 15) to the MBA and 88 
shown good correlation of anti-rp17 antibodies to other laboratory-based treponemal tests (measuring long-89 
lived responses) and of anti-TmpA antibodies to non-treponemal tests (reflecting current or recent infection) 90 
(16). The ability of TmpA responses to track current infection potentially allows it to substitute for RPR testing in 91 
large-scale surveillance work. There is a need to assess the dynamics of this test before and after intervention to 92 
increase confidence that TmpA responses wane in the way that RPR titers do after infection has been cleared. In 93 
this study, we measured antibodies to rp17 and TmpA using MBA in dried blood spots taken from individuals 94 
before and after azithromycin treatment for active yaws. We nested our investigation within a trial for 95 
comparing different doses of azithromycin for yaws conducted in Ghana and Papua New Guinea. 96 
Methods 97 
Study Design and Sample Collection  98 
Samples were collected in the context of a randomized, controlled, open-label non-inferiority trial of 20 mg/kg 99 
versus 30 mg/kg azithromycin for the treatment of yaws. Participant recruitment has been described previously 100 
(17). Briefly, children aged 6–15 years were invited to participate based on the following criteria: presence of a 101 
clinical lesion consistent with infectious primary or secondary yaws and the DPP syphilis screen and confirm 102 
assay that was positive for both treponemal and non-treponemal antibodies (18). Three children in the sub-103 
study presented here were sampled out of protocol (age 5 years) but were included in the analysis. Children 104 
were seen at baseline for enrolment, initial data collection, and antibiotic treatment, and again for follow-up at 105 
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4 weeks and 6 months. The current analysis used only blood samples collected at baseline and 6 months after 106 
treatment, at which time points venous blood samples were collected. Serum samples were sent to CDC for 107 
quantitative TPPA and RPR testing. Swabs were collected from lesions and tested at CDC for the presence of T. 108 
pallidum DNA by real-time PCR (TP-PCR); data from these investigations were previously published (17). For the 109 
current study we included individuals who had positive yaws serology at enrollment into the original trial, who 110 
had been seen for a 6-month follow-up visit, and for whom residual paired serum samples were available.  111 
Multiplex Bead Assay 112 
Serum samples were diluted in 1.5 mL tubes to a final concentration of 1:400 in Buffer B (1X PBS, 0.5% polyvinyl 113 
alcohol, 0.8% polyvinylpyrrolidone, 0.5% casein, 0.3% Tween-20, 0.02% sodium azide containing 3 µg/mL of 114 
Escherichia coli extract) and incubated overnight at 4°C.  115 
Total IgG was detected by incubating diluted specimens in duplicate in a 96-well plate with beads coupled to 116 
rp17 or TmpA, and then detecting antigen-specific IgG with monoclonal anti-human IgG and IgG4 and 117 
streptavidin-linked R-phycoerythrin reporter, as described previously (16). Antibody binding was reported as 118 
median fluorescence intensity (MFI) using a Luminex 200 instrument (Luminex Corporation, Austin, TX, USA) 119 
with the background fluorescence from a Buffer B-only blank subtracted (MFI-BG). Specimens for which the 120 
coefficient of variation (CV) was >15% between the MFI-BG of duplicate wells for any bead were repeated. Pre- 121 
and post-treatment samples from the same individual were run on the same plate to minimize variation. 122 
Cutoffs for seropositivity were determined by receiver operating characteristic curves. The positive panel 123 
consisted of 18 samples from 4–15-year-old children from yaws-endemic areas who were positive by both TPPA 124 
and RPR, and the negative panel consisted of 162 samples from individuals living in yaws-endemic areas that 125 
were negative by both TPPA and RPR. The cutoff was set as the midpoint between the highest MFI-BG value in 126 
the negative panel and the lowest MFI-BG value in the positive panel.  127 
Data analysis 128 
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Data were analyzed using SAS software, Version 9.4 (SAS Institute Inc., Cary, NC, USA). Descriptive analyses were 129 
performed to compare the results of conventional serological testing performed in the original trial to Luminex-130 
based serological analysis conducted in the current study. For various analyses, data were stratified by baseline 131 
TP-PCR positivity, RPR titer decline from baseline to 6 months after antibiotic treatment, or serological cure 132 
(defined as a 4-fold decline in RPR titer or seroreversion of the RPR test result by 6 months). Confidence 133 
intervals for the median percent changes in rp17 and TmpA MFI-BG were calculated using order statistics. The 134 
percent changes did not have a normal distribution, and therefore required the use of non-parametric methods. 135 
Assay performance 136 
A validation panel was run to determine the repeatability and dilutional linearity of the assays. Initially, six high-137 
titer archived samples were run in single wells with two-fold dilutions ranging from 1:400 to 1:12,800 to 138 
establish a rough estimate of the range to be used for precision and dilutional linearity testing. Then, high titer 139 
sera from the study samples (n= 10) were selected and a three-point (1:400, 1:4000, 1:8000) dilution series run 140 
to identify ranges for validation testing (Figure 1). From these six samples, four were selected for validation 141 
testing. Samples were diluted serially at four-fold intervals ranging from 1:4000 to 1:65,536,000 and run in 142 
duplicate on five days over the course of two weeks by one technician. Only data through the 1:4,096,000 143 
dilution are shown.  144 
Ethics 145 
Ethical approval for the trial and this sub-study was obtained from the London School of Hygiene & Tropical 146 
Medicine (Ref 8832),  Ghana Health Service Ethical Review Committee (Ref GHS-ERC: 3), the Papua New Guinea 147 
Institute of Medical Research (IRB number 1504), the Papua New Guinea Medical Research Advisory Committee 148 
(MRAC No. 14.31), the WHO Ethics Review Committee (Protocol ID RPC720), and the Centers for Disease Control 149 
and Prevention (6474/7285).  150 
Results 151 
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In the original trial, 406 participants had positive yaws serology at baseline and had been seen for a 6-month 153 
follow-up visit. Of these participants, residual paired serum samples were available from 344 participants 154 
(84.7%) and were included in the current study. Demographic information is shown in Table 1. Study participants 155 
were Ghanaian and Papua New Guinean children aged 5–15 years. The proportion of the sample that was male 156 
(71.5%, n = 246) was similar to the proportion of males seen in the original study (71.8%). The median age of 157 
participants contributing sera to the current study was 11 years.  158 
At baseline, 342 (99.4%) of 344 samples tested positive for antibodies against rp17, and 337 (98.0%) tested 159 
positive for antibodies against TmpA. Of samples from TP-PCR-positive children collected at baseline (n = 129, 160 
37.5%), 127 (98.4%) tested positive for antibodies against rp17 and 128 (99.2%) tested positive for antibodies 161 
against TmpA. 162 
Assay Performance Characteristics 163 
Performance tests showed a high reactivity (>97%) to rp17 and TmpA antigens in samples from individuals 164 
testing positive by TPPA. Repeatability assessment showed that CVs from inter-plate replicates were consistently 165 
<10% across the linear range for rp17 and <15% for TmpA, as shown in Table 2. The dilutional linearity of each 166 
assay is shown in Figure 1.  Dilution curves were run starting at 1:4000 (10-fold higher than run during the 167 
standard MBA protocol) using 4-fold dilutions. Signals associated with TmpA-specific responses were 168 
consistently lower than those against rp17 and showed signal reduction in a linear range at lower dilutions than 169 
rp17-specific responses. To assess inter-assay precision, we ran the two antigens as multiplex, so the MFI-BG for 170 
anti-TmpA fell below the cutoff in a few dilutions, resulting in fewer points in linear range. The Luminex-200 171 
used for the analysis has a maximum channel range of 32,766, meaning that any signal stronger than that will 172 
saturate the system, potentially limiting our ability to get meaningful quantitative data from the rp17 antigen 173 
when MFI-BG >25,000.  174 
Changes in anti-treponemal antibody levels after treatment 175 
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The median rp17 change was a 3.2% reduction (Table 3) in MFI-BG after excluding an outlier sample that had a 176 
7000% increase in MFI-BG (fold-change of 0.25 or 0.5 indicates an increase in RPR titer). Participants who 177 
achieved serological cure (i.e. ≥4-fold decrease in RPR titer or seroreversion) after 6 months had a median rp17 178 
reduction of 4.8%, while for participants who did not achieve serological cure, the overall median change was a 179 
1.9% reduction. The median TmpA change was a 53.8% reduction in MFI-BG after removing an outlier sample 180 
that had a 3800% increase in MFI-BG.  Among participants who achieved serological cure after 6 months, the 181 
median TmpA change was a 68.3% reduction in MFI-BG, while for those who did not achieve serological cure, 182 
the median TmpA change was a 33.5% reduction in MFI-BG. Changes in TmpA responses stratified by RPR titer 183 
are shown in Table 3.  184 
Individuals with TP-PCR-positive swabs showed greater percent change in MFI-BG after treatment for both 185 
antigens than those testing PCR-negative (Table 4). 186 
Discussion 187 
Multiplex-based serology has the potential to add value to surveys and public health programs by generating 188 
seroprevalence data on more than one disease of public health interest from a single sample set. A disease that 189 
would particularly benefit from this approach is yaws, which has a WHO eradication target by 2030 but little 190 
information available about where interventions are currently required and insufficient funding to generate 191 
epidemiological data through widespread stand-alone mapping efforts, as has been done for trachoma, as an 192 
example (19). Traditional yaws laboratory diagnosis is based on serology, but these tests utilize readouts such as 193 
particle agglutination or antibodies against lipid antigens that are not well suited to the multiplex bead-based 194 
platform that facilitates integrated surveillance. Here, we show good test performance for two treponemal 195 
antigens (rp17 and TmpA) that run on the MBA, with the expected downward trends in antibody signals from 196 
TmpA in children from Ghana and PNG following treatment of yaws with azithromycin. Responses to both 197 
antigens not only show good analytical performance against positive and negative control panels but also an 198 
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excellent dilutional linearity and repeatability, particularly for rp17, which demonstrated higher inter-operator 199 
precision than TmpA.  200 
While we noted an overall downward trend in TmpA-specific antibody levels following treatment, our 6-month 201 
time frame for follow-up may not have been long enough to detect large changes and was specifically not 202 
sufficiently long to observe seroreversion from positive to negative. This is also a limitation of the RPR test, for 203 
which TmpA testing is broadly analogous. Serological cure on standard non-treponemal serology is defined as 204 
either seroreversion or a 4-fold decrease in titer: current standards do not require undetectability of antibody. 205 
Our test performance data suggest that within the linear range, decreases of 30% or more are likely to be 206 
technically meaningful (in terms of the repeatability of the assay), and we found an association between the 207 
percentage change in TmpA and the RPR titer fold change. Additional data would be needed to define 208 
biologically meaningful decreases in the TmpA signal after treatment.  209 
 210 
Our data support the idea that testing for antibodies to rp17 and TmpA could be informative for yaws 211 
surveillance in previously endemic countries for which the current yaws status is unknown. The slower decline in 212 
TmpA-specific antibody responses compared to RPR titers after treatment may have a programmatic advantage 213 
for this application because a negative TmpA response would indicate a more prolonged interval since the most 214 
recent infection in an individual. On the other hand, more than six months’ follow-up of treated patients will be 215 
needed to determine whether TmpA will be useful for certifying a of lack of ongoing transmission in a recently 216 
endemic country that has implemented a yaws elimination program. Such studies would allow us to determine 217 
the time to seroreversion in cohorts with yaws and inform guidance on optimal timing for assessing evidence of 218 
interruption of transmission using TmpA. 219 
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Table 1. Demographic information on individuals providing samples in for this multiplex bead assay (MBA) sub-231 
analysis, compared to original study sample set. 232 
 233 
  MBA sub-analysis Original sample set (17) 
  n (%) n (%) 
Total 344 (100) 406 (100) 
Male 247 (71.8) 290 (71.4) 
Female 97 (28.2) 116 (28.6) 
Age (years)     
5 3 (0.9) 3 (0.7) 
6 24 (7.0) 32 (7.9) 
7 37 (10.8) 40 (9.9) 
8 42 (12.2) 49 (12.1) 
9 37 (10.8) 47 (11.6) 
10 43 (12.5) 57 (14.0) 
11 47 (13.7) 47 (11.6) 
12 38 (11.0) 47 (11.6) 
13 3 1 (9.0) 37 (9.1) 
14 22 (6.4) 25 (6.2) 
15 20 (5.8) 22 (5.4) 
 234 
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Table 2.  Inter-assay precision of multiplex bead assay to measure antibodies against treponemal antigens rp17 236 
and TmpA. CV = coefficient of variation; MFI-BG = median fluorescence intensity with background subtracted. 237 
 238 
  sample 1 sample 2 sample 3 sample 4 
rp17     
  
    
 
  
Dilution Factor MFI-BG %CV MFI-BG %CV MFI-BG %CV MFI-BG %CV 
4000 27788 5.7 26980 7.1 26663 6.6 27505 5.2 
16000 15954 4.1 14752 4 8416 8.2 15056 4.4 
64000 2382 5.9 2326 7.5 1238 6.7 2538 7.3 
256000 426 7.6 405 3.1 233 9.4 439 7.9 
1024000 107 6.8 92 2.4 62 7.8 93 10.8 
4096000 25 8.6 205 2.4 16 25.9 19 16.6 
TmpA     
  
    
 
  
Dilution Factor MFI-BG %CV MFI-BG %CV MFI-BG %CV MFI-BG %CV 
4000 2103 11.3 3314 6.3 2755 7.3 834 4.4 
16000 376 7.8 750 11.5 451 7.7 131 7.5 
64000 64 12.6 139 9.8 80 16.9 24 12 
256000 16 20.5 27.5 8.4 16 13.5 5.5 40 
1024000 4.5 43.2 9 15.3 6 21.1 6 90 
4096000 2 71.3 9.5 24.7 1.5 129.8 0.5 418 
 239 
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Table 3. Median percent changes in antibody responses to treponemal antigens rp17 and TmpA in multiplex 242 
bead assay, stratified by decrease in rapid plasma reagin (RPR) titer. 95% confidence intervals (CI) calculated 243 
without normal distribution assumption. 244 
 
rp17 Median % Change TmpA Median % Change 
RPR Titer Decline Point Estimate 95% CI Point Estimate 95% CI 
0.25 (n=1) -8.1 - -35.9 - 
0.5 (n=14) -2 (-2.9, 0.3) -20.7 (-33.5, 5.6) 
1 (n=40) -1.8 (-3.1, -1) -32.7 (-41.4, -22.6) 
2 (n=67) -1.9 (-2.7, -1.2) -35.1 (-43.1, -28.3) 
4 (n=63) -2.7 (-3.8, -2.1) -53.1 (-61.7, -49.6) 
8 (n=52) -3.8 (-5.9, -2.8) -59.4 (-70.8, -48.9) 
16 (n=28) -10.2 (-18.9, -6.4) -77.2 (-85.3, -70.6) 
32 (n=10) -7.4 (-52.5, -1.9) -78.8 (-91.9, -60.5) 
64 (n=6) -26 (-82.2, -8.4) -91.3 (-96.5, -79) 
128 (n=2) -6.1 (-10.9, -1.3) -75.5 (-75.8, -75.2) 
Seroreversion (n=60) -26.8 (-60.3, -4.6) -83 (-89.2, -69.1) 
 245 
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Table 4. Median Percent Changes in antibody responses to rp17 and TmpA in multiplex bead assay stratified by 248 
PCR result. 95% Confidence Intervals calculated without normal distribution assumption. 249 
 
TmpA Median % Change rp17 Median % Change 
 
Point Estimate 95% CI Point Estimate 95% CI 
All (n=343) -53.5 (-57.8, -50.2) -3.1 (-4.1, -2.8) 
PCR Negative (n=215) -42.4 (-49.6, -37.3) -2.6 (-3.1, -2.1) 
PCR Positive (n=128) -75.1 (-80.8. -68.3) -7.8 (-12.3, -4.1) 
  250 
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Figure 1. Test performance of multiplex bead assay to detect antibodies against rp17 (top) and TmpA (bottom). 322 
Each line represents a dilution curve for 4 different samples. Error bars are standard error of triplicate runs on 5 323 
separate plates.  S=sample, MFI-BG = median fluorescence intensity with background subtracted. 324 
 325 
Figure 2.  Percentage change in rp17 (left) and TmpA (right)-specific antibody responses following treatment, 326 
stratified by rapid plasma reagin (RPR) titer change. Seroreversion indicates RPR=0 at the 6-month timepoint. 327 
Five outliers for which >anti-TmpA responses increased by >100% were excluded from the graph. Boxes show 328 
median and inter-quartile range and whiskers show 1.5 x the inter-quartile range.  MFI-BG = median 329 
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